Current Edition


Incyte withdraws cancer drug from FDA review after discussions with regulator

Dive Brief: Incyte is pulling its application for an experimental lymphoma medicine after determining that the Food and Drug Administration’s requirements for confirmatory studies would …

Continue Reading →

Two cancer cell therapy studies succeeded. Why did a third fail?

In two major clinical trials, researchers found cell therapy dramatically outperformed the standard of care used for the past few decades to counter a common …

Continue Reading →